View white papers from other Pharmaceutical sectors:
1-8 of 8 results
ASEBIO Report 2010
The most salient indicators include the almost 7% rise in the number of biotech R&D personnel employed and the over 5% growth in private R&D expenditure. In addition, companies carrying out biotechnology R&D grew 12%. Other output indicators are also noteworthy, such as the number of patent applications, which virtually doubled (up 85% in the past year). These indicators confirm the efficiency and strength of the national bioindustry sector.
Inward Investment > White Papers
Inward Investment > White Papers
Draft Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilisation to the Convention on Biological Diversity
The biotechnology industry is poised to be a critical player in the quest for innovative technologies in a variety of sectors, including medical, agricultural and industrial arenas. The industry is uniquely suited to collaborate and partner with organisations and institutions around the world including in the developing world, which in turn may provide benefits and increases capacity for these countries.
Inward Investment > White Papers
Inward Investment > White Papers
Drug Licensing Activity Report Q1 2010
After a stellar rise in Q4 2009, the total value of drug licensing agreements has taken a nosedive in Q1 2010. The quarter has seen 133 agreements valued at USD 8.4bn, a staggering decrease of 52% by value from Q4 2009, in which 146 agreements with a total value of USD 17.4bn were announced.
Inward Investment > White Papers
Inward Investment > White Papers
Licensing Agreement League Table of Legal Advisors Q1 2010
Cooley Godward Kronish tops the Q1 global league table ranked by value with three deals totaling US$1,665m. In terms of volume, Baker & McKenzie leads the pack with five transactions worth US$4m and is followed by Cooley Godward Kronish.
Inward Investment > White Papers
Inward Investment > White Papers
Outlining the Role of Genoma España in Promoting the Sector, General Director Rafael Camacho Fumanal Explores the Relevance of Biotechnology in Spain
The Ministry of Science and Innovation, through its Secretary General of Innovation, has made one of its primary goals the improvement of the competitive capacity of the Spanish productive model. In doing so, Spain will not only be able to reach a sustainable economic growth but, in turn, will be able to generate qualified employment, stimulate the traditional sectors, strengthen its current contributions in R&D, and create companies in the new and defiant sectors.
Inward Investment > White Papers
Inward Investment > White Papers
ProtoDynamic Therapy: A Novel Therapeutic Concept for Inflammation and Cancer
The newly introduced term protodynamic can be defined as a proton-derived force that produces a change in a living cell. The basic idea is to transport hydrogen ions (H+ or protons) from the mildly acidic extracellular medium into the cell, which causes intracellular acidification. The protodynamic mode of action and the efficacy of cis-UCA in various models of inflammation and cancer will be briefly presented in this paper.
Inward Investment > White Papers
Inward Investment > White Papers
Success Cases of Biotechnology and Genomics in Medicine, Food, Agriculture and Industry Sectors
This document is the result of a survey of biotechnology "success stories" performed by Genoma España. It consists of case studies in which biotechnology and genomics were successfully introduced into medicine, food and agriculture and industrial processes. The study of real cases of success gives a concrete and direct view on how these new technologies were used to solve existing problems, address new markets and contribute to industrial sustainability.
Inward Investment > White Papers
Inward Investment > White Papers
1
1-8 of 8 results